RxDoctor Payments Data

Nathaniel Welly, PA

Medical · Cottonwood, AZNPI 1881741726

Payments from drug & device makers

$4,311in general payments, 2019–2025

Across 208 payments — averaging $20.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$840
  • AstraZeneca$773
  • Amgen$460
  • Pfizer$321
  • Edwards Lifesciences$320
  • GSK$274
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$4,311100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,311 in reported general payments places this provider in the 80th percentile of 748 medical providers in Arizona.

See all medical providers in Arizona

Medicare billing

Part B allowed, 2024
$314,946
Medicare patients
409
Services billed
6,409

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide78$78,487
EliquisApixaban88$72,648
FarxigaDapagliflozin Propanediol96$69,339
JanuviaSitagliptin Phosphate52$51,543
TrulicityDulaglutide43$51,364
Trelegy ElliptaFluticasone/Umeclidin/Vilanter65$47,319
Breztri AerosphereBudesonide/Glycopyr/Formoterol57$40,652
JardianceEmpagliflozin42$40,630
OzempicSemaglutide35$38,620
XareltoRivaroxaban24$30,120
Combivent RespimatIpratropium/Albuterol Sulfate42$29,030
Spiriva RespimatTiotropium Bromide35$23,682
MyrbetriqMirabegron33$22,738
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog47$20,292
Breo ElliptaFluticasone/Vilanterol32$19,858

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$202$129,851121 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$773$113,837165 claims
Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat, Stiolto Respimat$72$110,009132 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$274$81,116134 claims
PfizerEliquis, Premarin$321$76,149100 claims
Novo NordiskOzempic$95$38,62035 claims
Astellas Pharma US IncMyrbetriq$67$22,73833 claims
AbbVieLinzess$840$17,45327 claims
NovartisEntresto$50$15,55013 claims
Eisai Inc.Dayvigo$79$7,88618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 748 medical providers in Arizona.

Other medical in Cottonwood

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →